Finabase

    • Login
    • Categories
    Home Watchlists Portfolios Map Forex Futures Crypto Comparisons Alerts Screeners Backtests vTrading Settings Forum
    1. Home
    2. BCRX
    • Alert
    • Note
    BCRX
    BioCryst Pharmaceuticals, Inc.
    10.88
    +
    0.12
    1.12%
    9 x 10.86
    15 x 10.87
    bid
    ask
    16696 @ 03:50 PM
    10.88+0.00 (0.00%)
    Bearish 29
    Bullish 76
    sentiment
    10.33
    day range
    10.95
    7.89
    52 week range
    19.76
    03:50 PM
    V: 3.45M
    C: 10.88
    L: 10.33
    H: 10.95
    O: 10.84
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close10.76
    Open10.84
    Low10.33
    High10.95
    Volume3.45M
    Avg. Volume4.96M
    Market Cap2.02B
    Inst. Own71.62%
    Beta2.51
    Short Ratio6.64
    Div & Yield0.00 /
    EPS-1.07
    P/E
    1yr Target17.45
    50day MA9.60
    200day MA13.40
    ^DJI
    Dow Jones Industrial Average
    31438.30
    12:00 AM
    -
    62.40
    0.20%
    ^IXIC
    NASDAQ Composite
    11524.60
    12:00 AM
    -
    83.00
    0.72%
    ^GSPC
    S&P 500
    3900.11
    12:00 AM
    -
    11.63
    0.30%
    AAPL
    141.98
    +0.32 (0.23%)
    Apple Inc.
    141.66
    1022 @ 03:50 PM
    3 x 141.10
    7 x 141.11
    +
    0.00
    0.00%
    GOOG
    2338.00
    +5.55 (0.24%)
    Alphabet Inc.
    2332.45
    1 @ 03:50 PM
    1 x 2329.99
    1 x 2331.29
    -
    38.31
    1.62%
    AMZN
    113.60
    +0.38 (0.34%)
    Amazon.com, Inc.
    113.22
    1 @ 03:50 PM
    1 x 112.96
    3 x 112.97
    -
    3.24
    2.78%
    MSFT
    265.23
    +0.34 (0.13%)
    Microsoft Corporation
    264.89
    3 @ 03:50 PM
    2 x 263.64
    1 x 263.67
    -
    2.81
    1.05%
    BABA
    118.82
    +0.09 (0.08%)
    Alibaba Group Holding Limited
    118.73
    1 @ 04:00 PM
    1 x 117.00
    1 x 120.30
    +
    1.11
    0.94%
    NFLX
    189.14
    +0.00 (0.00%)
    Netflix, Inc.
    189.14
    49 @ 03:50 PM
    1 x 188.15
    1 x 188.22
    -
    1.71
    0.90%
    TSLA
    735.81
    +1.05 (0.14%)
    Tesla, Inc.
    734.76
    14 @ 03:50 PM
    1 x 732.31
    1 x 732.66
    -
    2.36
    0.32%
    NVDA
    168.97
    +0.28 (0.17%)
    NVIDIA Corporation
    168.69
    100 @ 03:50 PM
    2 x 168.13
    3 x 168.16
    -
    2.57
    1.50%
    AMD
    86.25
    +0.09 (0.10%)
    Advanced Micro Devices, Inc.
    86.16
    500 @ 03:50 PM
    3 x 86.06
    12 x 86.08
    -
    0.92
    1.06%
    MU
    58.95
    +0.17 (0.29%)
    Micron Technology, Inc.
    58.78
    389 @ 03:50 PM
    4 x 58.71
    2 x 58.72
    +
    0.34
    0.58%
    SPY
    389.20
    +0.61 (0.16%)
    SPDR S&P 500 ETF Trust
    388.59
    1 @ 06:02 PM
    13 x 388.80
    5 x 388.87
    -
    1.49
    0.38%
    TQQQ
    27.49
    +0.17 (0.62%)
    ProShares UltraPro QQQ
    27.32
    25 @ 03:50 PM
    100 x 27.10
    69 x 27.11
    -
    0.66
    2.36%
    BRK-A
    414500.00
    -3200.00 (0.77%)
    Berkshire Hathaway Inc.
    417700.00
    11 @ 04:02 PM
    13 x 412000.00
    8 x 425555.00
    +
    299.00
    0.07%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison defenseworld.net •
    BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) seekingalpha.com •
    Stocks Rally as Major Indexes Look to End Losing Streaks schaeffersresearch.com •
    Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like uk.sports.yahoo.com •
    Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? zacks.com •
    Why BioCryst Pharmaceuticals Topped the Market Today fool.com •
    Profile ...
    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2022-08-04 2022-06 -0.36 N/A N/A N/A
    2022-05-05 2022-03 -0.39 -0.4 -0.01 -2.56%
    2022-02-23 2021-12 -0.31 -0.4 -0.09 -29.03%
    2021-11-03 2021-09 -0.3 -0.33 -0.03 -10.00%
    2021-08-05 2021-06 -0.22 -0.24 -0.02 -9.09%
    2021-05-06 2021-03 -0.26 -0.36 -0.1 -38.46%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2022-04-18 Barclays Downgrade Overweight Equal-Weight
    2022-04-12 RBC Capital Upgrade Sector Perform
    2022-04-11 B of A Securities Downgrade Buy Neutral
    2022-04-11 Oppenheimer Upgrade Outperform
    2021-12-10 Oppenheimer Upgrade Outperform
    2021-11-04 RBC Capital Upgrade Sector Perform
    Insider Holder ...
    Date Name Relation Quantity Description
    2022-06-06 ABERCROMBIE GEORGE B Director 12.87K Stock Award(Grant)
    2022-06-06 ASELAGE STEPHEN J Director 46.59K Stock Award(Grant)
    2022-06-06 GALSON STEVEN K Director 12.87K Stock Award(Grant)
    2022-06-06 HEGGIE THERESA Director 30.23K Stock Award(Grant)
    2022-06-06 HUTSON NANCY J Director 77.94K Stock Award(Grant)
    2022-06-06 INGRAM ROBERT ALEXANDER Director 95.00K Stock Award(Grant)
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2022-03-30 Blackrock Inc. 14.10M 229.30M 7.60%
    2022-03-30 Vanguard Group, Inc. (The) 13.21M 214.75M 7.12%
    2022-03-30 Baker Brothers Advisors, LLC 12.71M 206.68M 6.85%
    2022-03-30 FMR, LLC 8.41M 136.82M 4.53%
    2022-03-30 State Street Corporation 7.46M 121.34M 4.02%
    2022-03-30 Pictet Asset Management SA 5.11M 83.04M 2.75%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2022-03-30 Vanguard Total Stock Market Index Fund 5.26M 85.54M 2.83%
    2022-04-29 Fidelity Select Portfolios - Biotechnology 4.19M 38.95M 2.26%
    2022-04-29 iShares Russell 2000 ETF 3.96M 36.81M 2.14%
    2022-04-29 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3.71M 34.50M 2.00%
    2022-03-30 Vanguard Extended Market Index Fund 2.39M 38.83M 1.29%
    2022-03-30 Vanguard Small-Cap Index Fund 2.25M 36.59M 1.21%
    Dividend ...
    Dividend Date
    0 2014-06-11
    0 2014-06-05
    0 2014-05-20
    0 2014-05-16
    0 2014-04-02
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • R
      rncolucci last edited by

      Please someone explain the sudden change in volume, in layman’s terms, Tysm

      1 Reply Last reply Reply Quote 0
      • R
        rncolucci last edited by

        Please can someone explain the volume? I’m a newer trader. In layman’s terms. Tysm

        1 Reply Last reply Reply Quote 0
        • R
          rncolucci last edited by

          Meant to say write. I misspelled because I’m so upset.

          1 Reply Last reply Reply Quote 0
          • R
            rncolucci last edited by

            Write. Sorry. I can spell. Lol.

            1 Reply Last reply Reply Quote 0
            • R
              rncolucci last edited by

              I am not a big time investor. I’m stuck in this pos stock. I’m now convinced more then ever this Company is Shady. I had 30 shares limit buy at 3.95. I saw it drop to pick it up then right back up. I don’t know much but I’m convinced this is rigged. It’s doing it again as I right this. Dipping down sudden then back up.

              1 Reply Last reply Reply Quote 0
              • R
                rncolucci last edited by

                It’s going nowhere.

                1 Reply Last reply Reply Quote 0
                • R
                  rncolucci last edited by

                  Any year now. Maybe 2022 will be the year

                  1 Reply Last reply Reply Quote 0
                  • R
                    rncolucci last edited by

                    If Gladisvir was even possibly going to be a contender in Covid wouldn’t there be some shred of news out on that lately? I hope the positive hopes are correct but it feels like grasping at straws at this point. This stock needs to S—- or get off the pot. There’s just crickets on BCRX.

                    1 Reply Last reply Reply Quote 0
                    • R
                      rncolucci last edited by

                      It just keeps getting better and better. Nightmare stock

                      1 Reply Last reply Reply Quote 0
                      • R
                        rncolucci last edited by

                        Shady Shady something is not right here. Controlled stock. Live and learn. First dilution then you notice the pattern.

                        1 Reply Last reply Reply Quote 0
                        • R
                          rncolucci last edited by

                          Manipulated stock. Want out. Waste of time.

                          1 Reply Last reply Reply Quote 0
                          • R
                            rncolucci last edited by

                            Let’s be honest this stock is broken. NG

                            1 Reply Last reply Reply Quote 0
                            • R
                              rncolucci last edited by

                              Same volume same price range day in and day out. Like watching paint dry

                              1 Reply Last reply Reply Quote 0
                              • R
                                rncolucci last edited by

                                                                  Why doesn’t this stock ever move? If I was even ,I’d get out and buy back later. It just shows no signs of life.  
                                
                                1 Reply Last reply Reply Quote 0
                                • R
                                  rncolucci last edited by

                                  It’s just stuck! Zzzzz

                                  1 Reply Last reply Reply Quote 0
                                  • R
                                    rncolucci last edited by

                                    Re Dexamethasone is all you need, that news states it’s for severe cases and patients are already vented. The key would be meds that treat you before you get to that point.

                                    1 Reply Last reply Reply Quote 0
                                    • R
                                      rncolucci last edited by

                                      @Vafa sorry my words connected. Can’t find edit here.

                                      1 Reply Last reply Reply Quote 0
                                      • R
                                        rncolucci last edited by

                                        @Vafabbut when will that news hit be? The last news didn’t do anything imo.

                                        1 Reply Last reply Reply Quote 0
                                        • R
                                          rncolucci last edited by

                                          Company still selling shares at 4.50 target? They are still raising cash? How many shares do they have left to sell?

                                          1 Reply Last reply Reply Quote 0
                                          • R
                                            rncolucci last edited by

                                            Each new day ends in hope for the next day. Trying hard to remain positive, too many over paid shares to turn back now. Frustrated. Bought before the dilution.

                                            1 Reply Last reply Reply Quote 0
                                            • 1
                                            • 2
                                            • 15
                                            • 16
                                            • 17
                                            • 18
                                            • 19
                                            • 18 / 19
                                            • First post
                                              Last post
                                            • ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison
                                              defenseworld.net •

                                            • BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)
                                              seekingalpha.com •

                                            • Stocks Rally as Major Indexes Look to End Losing Streaks
                                              schaeffersresearch.com •

                                            • Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like
                                              uk.sports.yahoo.com •

                                            • Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
                                              zacks.com •

                                            • Why BioCryst Pharmaceuticals Topped the Market Today
                                              fool.com •

                                            • 7 Cheap Biotech Stocks to Buy Now
                                              investorplace.com •

                                            • BioCryst to Present at Upcoming Investor Conferences
                                              globenewswire.com •

                                            • Why BioCryst Stock Lost Nearly 4% of Its Value Today
                                              fool.com •

                                            • Why BioCryst Stock Shot Nearly 5% Higher Today
                                              fool.com •

                                            • BioCryst to Report First Quarter 2022 Financial Results on May 5
                                              globenewswire.com •

                                            • Why BioCryst Pharmaceuticals Stock Sank Today
                                              fool.com •

                                            • Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
                                              fool.com •

                                            • Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
                                              zacks.com •

                                            • BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
                                              zacks.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Falling
                                              benzinga.com •

                                            • BioCryst to Present at Upcoming Investor Conference
                                              globenewswire.com •

                                            • Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
                                              benzinga.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Plunging Today
                                              benzinga.com •

                                            • Why BioCryst Pharmaceuticals Stock Slid Today
                                              fool.com •

                                            • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript
                                              seekingalpha.com •

                                            • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
                                              zacks.com •

                                            • Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?
                                              benzinga.com •

                                            • Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals
                                              seekingalpha.com •

                                            • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
                                              globenewswire.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
                                              fool.com •

                                            • BioCryst Pharmaceuticals Stock (BCRX): Why The Price Surged Today
                                              pulse2.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Jumping on Monday
                                              fool.com •

                                            • BioCryst Provides Tremendous Option Value
                                              seekingalpha.com •

                                            • BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
                                              seekingalpha.com •

                                            • BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
                                              zacks.com •

                                            • BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
                                              benzinga.com •

                                            • 7 Top Growth Stocks to Buy as We Step Into November
                                              investorplace.com •

                                            • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript
                                              seekingalpha.com •

                                            • Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
                                              fool.com •

                                            • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
                                              globenewswire.com •

                                            • BioCryst to Report Third Quarter 2021 Financial Results on November 3
                                              globenewswire.com •

                                            • 7 Best Growth Stocks to Buy and Hold for the Next 10 Years
                                              investorplace.com •

                                            • 2 Super-Charged Growth Stocks to Buy Now
                                              fool.com •

                                            • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
                                              globenewswire.com •

                                            • 3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
                                              fool.com •

                                            • NICE Recommends BioCryst's Hereditary Angioedema Med
                                              benzinga.com •

                                            • NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
                                              globenewswire.com •

                                            • What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
                                              seekingalpha.com •

                                            • BioCryst to Present at Upcoming Investor Conferences
                                              globenewswire.com •

                                            • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
                                              globenewswire.com •

                                            • US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
                                              benzinga.com •

                                            • U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
                                              globenewswire.com •

                                            • BioCryst Appoints Dr. Steven Galson to Board of Directors
                                              globenewswire.com •

                                            • BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
                                              globenewswire.com •

                                            • 2 Soaring Biotech Stocks With More Fuel in the Tank
                                              fool.com •

                                            • BioCryst Stock Jumps After Pulling Out $200M Equity Raise
                                              benzinga.com •

                                            • BioCryst Withdraws Public Offering
                                              globenewswire.com •

                                            • Why BioCryst Pharmaceuticals Rose 8% on Thursday
                                              fool.com •

                                            • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
                                              seekingalpha.com •

                                            • BioCryst Pharma Stock Heads Higher Thursday: Here's Why
                                              benzinga.com •

                                            • Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More
                                              247wallst.com •

                                            • 3 Biotech Stocks That Could Rocket Higher
                                              fool.com •

                                            • BioCryst to Report Second Quarter 2021 Financial Results on August 5
                                              globenewswire.com •

                                            • BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
                                              seekingalpha.com •

                                            • BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
                                              benzinga.com •

                                            • BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
                                              benzinga.com •

                                            • BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
                                              globenewswire.com •

                                            • ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
                                              globenewswire.com •

                                            • Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
                                              seekingalpha.com •

                                            • Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
                                              fool.com •

                                            • BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
                                              globenewswire.com •

                                            • 7 A-Rated Biotech Stocks to Buy Now
                                              investorplace.com •

                                            • BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
                                              seekingalpha.com •

                                            • Forget AMC, GameStop: Analyst Names 2 New Reddit Stocks Traders Should Watch
                                              benzinga.com •

                                            • Is BioCryst a Good Stock to Buy Now?
                                              fool.com •

                                            • Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
                                              zacks.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Jumping Today
                                              fool.com •

                                            • BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
                                              globenewswire.com •

                                            • Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?
                                              zacks.com •

                                            • BioCryst: Solid Delivery And Follow Through
                                              seekingalpha.com •

                                            • BCRX Stock: 24.35% Increase (From $10.68 To $13.28) Intraday Explanation
                                              pulse2.com •

                                            • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2021 Results - Earnings Call Transcript
                                              seekingalpha.com •

                                            • BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues
                                              benzinga.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Soaring Today
                                              fool.com •

                                            • BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
                                              globenewswire.com •

                                            • BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
                                              globenewswire.com •

                                            • BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
                                              globenewswire.com •

                                            • BCRX Stock Price: $15 Target By Piper Sandler
                                              pulse2.com •

                                            • BioCryst Technical Levels To Watch
                                              benzinga.com •

                                            • FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
                                              benzinga.com •

                                            • BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
                                              globenewswire.com •

                                            • BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls
                                              247wallst.com •

                                            • BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
                                              benzinga.com •

                                            • BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
                                              globenewswire.com •

                                            • Why BioCryst Pharmaceuticals Stock Is Falling Today
                                              fool.com •

                                            • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2020 Results - Earnings Call Transcript
                                              seekingalpha.com •

                                            • BioCryst Short-Sellers Lose Control
                                              seekingalpha.com •

                                            • BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
                                              globenewswire.com •

                                            • BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
                                              globenewswire.com •

                                            • Is it the right moment for investing in BioCryst Pharmaceuticals shares?
                                              invezz.com •

                                            • BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
                                              globenewswire.com •

                                            • BioCryst Shares Slide As Reddit-Induced Rally Peters Out
                                              benzinga.com •

                                            • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
                                              globenewswire.com •

                                            • Implied Volatility Surging for BioCryst (BCRX) Stock Options
                                              zacks.com •

                                            Copyright © 2022 finabase.io